A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization

• DOI: 10.1684/ejd.2023.4578
• Publication Date: 2024-03-11T09:23:48Z
• Authors: Sergio Vañó Galván; Bianca Maria Pira...; Pascal Reygagne; Paul Farrant; Catherine Reed; Erin Johansson; Simran Marwaha; Frederick Durand; Ulrike Blume-Peytavi

A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization severity and associated treatment utilizationBackground: Alopecia (AA), an autoimmune disease affecting the hair scalp, face, and/or body, can entail substantial psychological physical burden for patients.There is currently no international agreement how to treat AA approach may vary across countries.Objectives: This study investigated management clinical practice.Materials & Methods: Data from a point-in-time conducted France, Germany, Italy, Spain, United Kingdom, between October 2021-June 2022, were analysed adults with mild, moderate, severe AA, physician assessment.Dermatologists surveyed about factors used assess severity, goals, patterns including use wigs.Results: In total, 239 dermatologists reported 2,083 patients.Physicians' assessment goals predominantly driven by scalp loss.Topical intralesional corticosteroids most prescribed treatments mild moderate AA.Conventional immunosuppressants, oral Janus kinase inhibitors, topical immunotherapy generally increased therapy line.Wig was greatest AA.The primary reasons last change groups worsening condition, lack initial efficacy, loss response, group improvement condition.Findings similar countries.Conclusion: analysis provides insights into five countries confirms need more effective therapies, especially AA.